Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Risedronate + calcium is a combination pharmaceutical regimen used for the prevention and treatment of osteoporosis, especially in postmenopausal women and individuals with steroid-induced osteoporosis[1][3]. The combination consists of risedronate (a bisphosphonate) and calcium carbonate, typically administered as a weekly cycle with 1 risedronate tablet and 6 calcium tablets. - **Mechanism of Action:** Risedronate inhibits bone resorption by osteoclasts through direct binding to bone hydroxyapatite and inhibition of farnesyl pyrophosphate synthase, leading to osteoclast apoptosis and reduced bone breakdown[1][3][4]. Calcium carbonate is essential for bone formation and maintenance and helps to prevent calcium deficiency[1][3]. - **Primary Indication:** The regimen is used in osteoporosis (postmenopausal, steroid-induced), and may also be used for Paget's disease of bone and to reverse progression of osteoporosis[1][3]. - **Prescription Status:** Approved combination, available only with prescription[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on risedronate + calcium.